These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 33747756)

  • 21. Frontrunners in the race to develop a SARS-CoV-2 vaccine.
    Russell RL; Pelka P; Mark BL
    Can J Microbiol; 2021 Mar; 67(3):189-212. PubMed ID: 33264067
    [TBL] [Abstract][Full Text] [Related]  

  • 22. COVID-19: Coronavirus Vaccine Development Updates.
    Zhao J; Zhao S; Ou J; Zhang J; Lan W; Guan W; Wu X; Yan Y; Zhao W; Wu J; Chodosh J; Zhang Q
    Front Immunol; 2020; 11():602256. PubMed ID: 33424848
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The 2020 race towards SARS-CoV-2 specific vaccines.
    Karpiński TM; Ożarowski M; Seremak-Mrozikiewicz A; Wolski H; Wlodkowic D
    Theranostics; 2021; 11(4):1690-1702. PubMed ID: 33408775
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bioinspired and Biomimetic Nanomedicines.
    Chen Z; Wang Z; Gu Z
    Acc Chem Res; 2019 May; 52(5):1255-1264. PubMed ID: 30977635
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies.
    Frederiksen LSF; Zhang Y; Foged C; Thakur A
    Front Immunol; 2020; 11():1817. PubMed ID: 32793245
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Review of Current Vaccine Development Strategies to Prevent Coronavirus Disease 2019 (COVID-19).
    Bennet BM; Wolf J; Laureano R; Sellers RS
    Toxicol Pathol; 2020 Oct; 48(7):800-809. PubMed ID: 32926660
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biotechnology, nanotechnology and medicine.
    Contera S; Bernardino de la Serna J; Tetley TD
    Emerg Top Life Sci; 2020 Dec; 4(6):551-554. PubMed ID: 33295610
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lipid Nanoparticle Technology for Clinical Translation of siRNA Therapeutics.
    Kulkarni JA; Witzigmann D; Chen S; Cullis PR; van der Meel R
    Acc Chem Res; 2019 Sep; 52(9):2435-2444. PubMed ID: 31397996
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Nano-Bio Interactions of Nanomedicines: Understanding the Biochemical Driving Forces and Redox Reactions.
    Wang Y; Cai R; Chen C
    Acc Chem Res; 2019 Jun; 52(6):1507-1518. PubMed ID: 31149804
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SARS-CoV-2-mediated immune system activation and potential application in immunotherapy.
    Tan Y; Tang F
    Med Res Rev; 2021 Mar; 41(2):1167-1194. PubMed ID: 33185926
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Viral Evasion of the Complement System and Its Importance for Vaccines and Therapeutics.
    Mellors J; Tipton T; Longet S; Carroll M
    Front Immunol; 2020; 11():1450. PubMed ID: 32733480
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SARS-CoV-2 vaccine research and development: Conventional vaccines and biomimetic nanotechnology strategies.
    Huang L; Rong Y; Pan Q; Yi K; Tang X; Zhang Q; Wang W; Wu J; Wang F
    Asian J Pharm Sci; 2021 Mar; 16(2):136-146. PubMed ID: 32905011
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Progress and Pitfalls in the Quest for Effective SARS-CoV-2 (COVID-19) Vaccines.
    Flanagan KL; Best E; Crawford NW; Giles M; Koirala A; Macartney K; Russell F; Teh BW; Wen SC
    Front Immunol; 2020; 11():579250. PubMed ID: 33123165
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Protective Adaptive Immunity Against Severe Acute Respiratory Syndrome Coronaviruses 2 (SARS-CoV-2) and Implications for Vaccines.
    Manners C; Larios Bautista E; Sidoti H; Lopez OJ
    Cureus; 2020 Jun; 12(6):e8399. PubMed ID: 32499988
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Engineering vaccines and niches for immune modulation.
    Purwada A; Roy K; Singh A
    Acta Biomater; 2014 Apr; 10(4):1728-40. PubMed ID: 24373907
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recent advances in applying nanotechnologies for cancer immunotherapy.
    Mahjub R; Jatana S; Lee SE; Qin Z; Pauli G; Soleimani M; Madadi S; Li SD
    J Control Release; 2018 Oct; 288():239-263. PubMed ID: 30223043
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cancer Vaccine Immunotherapy with RNA-Loaded Liposomes.
    Sayour EJ; Mendez-Gomez HR; Mitchell DA
    Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30249040
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Perspectives in Peptide-Based Vaccination Strategies for Syndrome Coronavirus 2 Pandemic.
    Di Natale C; La Manna S; De Benedictis I; Brandi P; Marasco D
    Front Pharmacol; 2020; 11():578382. PubMed ID: 33343349
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Science and technology of the emerging nanomedicines in cancer therapy: A primer for physicians and pharmacists.
    Pillai G; Ceballos-Coronel ML
    SAGE Open Med; 2013; 1():2050312113513759. PubMed ID: 26770691
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Understanding the Host Innate Immune Responses against SARS-CoV-2 Infection and COVID-19 Pathogenesis.
    Kang YW; Park S; Lee KJ; Moon D; Kim YM; Lee SW
    Immune Netw; 2021 Feb; 21(1):e1. PubMed ID: 33728094
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.